Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.22 -3.31%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $85.7 million versus the consensus estimate of $90.36 million.
GUIDANCE:
2021 revenue guidance $375 - 405 million
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Upland Software (UPLD) Tops Q3 EPS by 11c ; Offers Guidance
- Dave Inc. (DAVE) Tops Q3 EPS by 31c; offers guidance
- Fastly, Inc. (FSLY) Tops Q3 EPS by 5c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
